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Abstract: Exercise simultaneously incites beneficial (e.g., signal) and harming (e.g., damage to
macromolecules) effects, likely through the generation of reactive oxygen and nitrogen species (RONS)
and downstream changes to redox homeostasis. Given the link between nuclear DNA damage
and human longevity/pathology, research attempting to modulate DNA damage and restore redox
homeostasis through non-selective pleiotropic antioxidants has yielded mixed results. Furthermore,
until recently the role of oxidative modifications to mitochondrial DNA (mtDNA) in the context of
exercising humans has largely been ignored. The development of antioxidant compounds which
specifically target the mitochondria has unveiled a number of exciting avenues of exploration which
allow for more precise discernment of the pathways involved with the generation of RONS and
mitochondrial oxidative stress. Thus, the primary function of this review, and indeed its novel
feature, is to highlight the potential roles of mitochondria-targeted antioxidants on perturbations
to mitochondrial oxidative stress and the implications for exercise, with special focus on mtDNA
damage. A brief synopsis of the current literature addressing the sources of mitochondrial superoxide
and hydrogen peroxide, and available mitochondria-targeted antioxidants is also discussed.
Keywords: exercise; MitoQ; reactive oxygen species; mitochondrial DNA damage;
cardiolipin peroxidation
1. Introduction
Mitochondria are recognised as multifaceted arbiters of the life and death of the cell, contributing
to numerous cell networks including metabolism and biosynthetic pathways [1,2]. During oxidative
phosphorylation, mitochondria generate a proton-motive force by oxidising nicotinamide adenine
dinucleotide (NAD), and transporting hydrogen ions through the inner mitochondrial membrane for
the purpose of adenosine 5-triphosphate (ATP) synthesis [3]. Reminiscence of its prokaryotic origin,
mitochondria have retained their own genome and while the majority of mitochondrial proteins are
regulated by the nuclear genome, a select number of respiratory proteins, and mitochondrial transfer
and ribosomal RNAs remain encoded by mitochondrial DNA (mtDNA) [4]. These proteins are vital
for the structure and function of the electron transport chain (ETC)—the series of reactions responsible
for the oxidation of reduced coenzymes (NADH and FADH2), which are products of glucose and fatty
acid catabolism.
Regular exercise has a plethora of health benefits associated with human longevity, primarily
through the prevention and management of chronic diseases [5]. These exercise-stimulated phenotypic
adaptations are a consequence of acute and chronic responses, which are largely thought to be
governed by redox-sensitive triggers (e.g., mitochondrial adaptation: sarcoplasmic calcium, ATP:ADP,
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NAD+:NADH, RONS) [3,6]. Although regular, moderately-intense exercise induces beneficial
adaptations [7], sporadic and strenuous bouts of exercise incite oxidative stress due to an augmented
production of reactive oxygen and nitrogen species (RONS) [8]. An accumulation of RONS impairs
cell function by oxidatively modifying nucleic acids, where DNA damage and insufficient repair may
potentially lead to mutagenic, clastogenic, and carcinogenic effects [9]. Currently, the majority of
exercise redox research has focused on nuclear DNA damage [10,11], with a scant understanding on the
relationship between exercise and mitochondrial redox dynamics in vivo. Further, evidence postulates
a clear connection between mitochondrial dysfunction and disease progression [12], primarily driven
by an increase in mitochondria ROS production and mtDNA damage [13,14]. This mtDNA damage
can function as a redox signal thereby inducing a physiological and/or simultaneous pathological
outcome as depicted in Figure 1 and briefly differentiated in Box 1.
Box 1. The Potential Downstream Beneficial and Pathological Signals of DNA Damage.
Under normal physiological circumstances, DNA undergoes numerous modifications from endogenous
sources of RONS, compounded by exogenous physical and chemical agents (i.e., UV-irradiation, pharmacological
drugs, DNA methylating agents, etc.). The current body of evidence demonstrates that high-intensity exercise is
a stimulus for DNA damage. However, the potential beneficial and detrimental responses of exercise-induced
DNA damage is yet to be fully elucidated. It is conceivable that an imbalance in this biological tug-of-war
between DNA damage and repair can result in a pathological outcome.
Beneficial, Health Enhancing Effects: Regular, moderate-intensity exercise increases the production of
RONS inciting damage to macromolecules, including DNA. Although complex, it has been proposed that
the increase in RONS (and potentially the macromolecular damage itself) can trigger the up-regulation of
transcription factors, and activate redox signals resulting in the enhanced capacity of the organism to overcome
greater stress. Ultimately, over time these exercise-mediated signals trigger adaptations to RONS handling by
influencing antioxidant enzyme capacity and DNA repair [15–19].
Detrimental Health Effects: Currently, the idea that exercise contributes to the development of a pathological
disease is a theorem, as opposed to a hypothesis with conclusive, demonstrable evidence. Indeed, whether DNA
damage is a cause or consequence of disease is an active area of research. Nevertheless, the premise involves the
generation of cell DNA oxidation products such as 8-Oxo-2′-deoxyguanosine (8-Oxo-dG), which is normally
removed and repaired by a DNA glycosylase (such as 8-oxoguanine DNA glycosylase—OGG1). However,
unpaired 8-Oxo-dG can lead to a stalling in DNA replication forks and G > T transversion mutations [20].
To date, research examining the efficacy of systemic antioxidant treatment as a potential therapeutic
to manipulate oxidative damage, and restore redox homeostasis, has produced mixed outcomes [21].
This may be due to inadequate dose and/or timing of antioxidant supplementation, poor bioavailability,
heterogeneous microenvironments in which antioxidants exert their action, antioxidant status of the
study population, and systemic distribution of the compound [22]. To overcome these limitations,
targeted compounds have been developed for clinical applications with a specific focus on mitochondria
such as MitoE [23], tiron [24–26], MitoQ [27,28] and MitoC [29]. In addition to the clinical perspective,
the development of mitochondria-targeted compounds has allowed for a more precise exploration of
in vitro/in vivo redox-sensitive processes associated with mitochondria redox dynamics.
The purpose of this review is to initially outline mitochondria superoxide and hydrogen peroxide
production (O2·−/H2O2), with an emphasis on antioxidants with potential therapeutic action. Secondly,
we outline the effects of exercise-mediated mitochondrial DNA damage and lipid peroxidation and the
potential role of targeted antioxidant supplementation.
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Figure 1. Cellular responses and downstream effects of mtDNA damage. The increased generation of 
ROS (and/or loss of mtDNA repair), and increase in lipid peroxidative products can potentiate 
mtDNA damage. Green shading represents the physiological and protective responses to mtDNA 
damage whereby mitochondria with excessive damage are segregated and compensated via fission 
and/or fusion, respectively, and are subsequently removed by mito/autophagy. Red shading indicates 
pathophysiological responses to mtDNA damage whereby excessive mtDNA damage can result in 
mtDNA mutations and eventual heteroplasmy; thus, causing a loss of mitochondrial function and 
potentially leading to organ pathology and disease. Adapted with permission from Van Houten et al. 
[30]. 
2. Mitochondrial Superoxide and Hydrogen Peroxide 
Mitochondrial O2−/H2O2 are generated by electron leaks from donor redox centres of the ETC and 
associated metabolic enzymes causing uni- and/or bi-valent reduction of oxygen [31]. Although it is 
well established that mitochondrial O2−/H2O2 are generated as products of oxidative phosphorylation, 
the contribution of the specific site(s) responsible has always been an area of conjecture. Early 
calculations postulated that 2–5% of total oxygen through the electron transport chain led to O2·- 
formation; later revised down to 0.15% [32–34]. Under contrived conditions of substrate supply and 
inhibition of normal electron transport, there are at least 11 mitochondrial sites that produce 
O2−/H2O2, which can be divided into the NADH/NAD+ and ubiquinol/ubiquinone (UQH2/UQ) 
isopotential groups: OF, BF, AF, PF, IF, IQ, IIF, IIIQo, GQ, EF, and DQ, each with different capacities [31,35]. 
Traditionally, the reduced flavin mononucleotide or the N-1a and N-1b iron–sulfur clusters from 
complex I (NADH + FMN → FMNH− + NAD+; FMNH + O2 → FMN + O2.-) and the ubiquinol oxidation 
site of complex III (SQ.- + O2 → Q + O2.-; Q pool- and membrane potential-dependent) are understood 
to be major sources of O2−/H2O2 in the respiratory chain [36–38]. Under appreciable substrate 
availability, a considerable amount of superoxide can also be generated through the tricarboxylic acid 
cycle dehydrogenases, when NADH/NAD+ ratios are high [39]. There is also the possibility that 
complex II can produce superoxide under physiological conditions (FADH- + O2 → FAD + O2·- ;[40]; 
however, it is likely that succinate and ubiquinol act as reducing equivalents when FADH has 
sufficient oxygen availability [41]. On a final point, one of the more interesting discoveries is the 
contribution of reverse electron transfer to mitochondrial superoxide production [42,43]. Reverse 
electron transfer may be stimulated by succinate, or inhibited through oxaloacetate, malonate and/or 
rotenone that are largely dependent on the pH gradient across the inner membrane [44,45], likely 
Figure 1. Cellular responses and downstream effects of mtDNA da age. The increased generation of
ROS (and/or loss of mtDNA repair), and increase in lipid peroxidative products can potentiate mtDNA
damage. Green shading represents the physiological and protective responses to mtDNA damage
whereby mitochondria with excessive damage are segregated and compensated via fission and/or fusion,
respectively, and are subsequently removed by mito/autophagy. Red shading indicates pathophysiological
responses to mtDNA damage whereby excessive mtDNA damage can result in mtDNA mutations and
eventual heteroplasmy; thus, causing a loss of mitochondrial function and potentially leading to organ
pathology and disease. Adapted with permission from Van Houten et al. [30].
2. Mitochondrial Superoxide and Hydrogen Peroxide
Mitochondrial O2−/H2O2 are generated by electron leaks from donor redox centres of the ETC and
associated metabolic enzymes causing uni- and/or bi-valent reduction of oxygen [31]. Although it is
well established that mitochondrial O2−/H2O2 are generated as products of oxidative phosphorylation,
the contribu ion of the specifi site(s) responsible has al a n area of conjecture. Early
calculations po tula ed tha 2–5% of total oxygen through the electro t rt chain led to O2·−
formation; later revis d down to 0.15% [32–34]. Under contrive itions of substrate supply and
inhibition of normal electron transport, there are at least 11 mitochondrial sites that produce O2−/H2O2,
which can be divided into the NADH/NAD+ and ubiquinol/ubiquinone (UQH2/UQ) isopotential
groups: OF, BF, AF, PF, IF, IQ, IIF, IIIQo, GQ, EF, and DQ, each with different capacities [31,35].
Traditionally, the reduced flavin mononucleotide or the N-1a and N-1b iron–sulfur clusters from
complex I (NADH + FMN→FMNH− + NAD+; FMNH + O2→FMN + O2.−) and the ubiquinol oxidation
site of complex III (SQ.− + O2→Q + O2.−; Q pool- and membrane potential-dependent) are understood
to be major sources of O2−/H2O2 in the respiratory chain [36–38]. Under appreciable substrate
availability, a considerable amount of superoxide can also be generated through the tricarboxylic acid
cycle dehydrogenases, when NADH/NAD+ ratios are high [39]. There is also the possibility that
complex II can produc superoxide under phys ological onditions (FADH− + O2→ FAD + O2·−; [40];
however, it is likely that succinate and ubiquinol act as reducing equivale s when FADH has sufficient
oxygen availability [41]. On a final point, one of the more interesting discoveries is the contribution of
reverse electron transfer to mitochondrial superoxide production [42,43]. Reverse electron transfer may
be stimulated by succinate, or inhibited through oxaloacetate, malonate and/or rotenone that are largely
dependent on the pH gradient across the inner membrane [44,45], likely leading to modifications in
ATP-sensitive potassium channels and mitochondrial O2−/H2O2 accumulation [46,47]. Although there
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has been significant progress in understanding superoxide production in respiratory chain complexes,
conjecture still exists as to the specific mechanisms involved. For an appreciable insight to the recent
discourse regarding the underlying biochemistry of superoxide production from the respiratory chain,
readers are directed to the excellent reviews by Cobley [48] and Nolfi-Donegan [49].
Aside from the respiratory chain, prototypic NADPH-oxidases (NOX) are commonly categorised
as a primary source of exercise-induced superoxide. More specifically, it appears NOX2 with its access
to the cytosolic domain, and the localisation of NOX4 to the mitochondria are the potential suspects
of exercise-mediated generation of superoxide and basal hydrogen peroxide (NOX4 only) [50–52].
Conjecture still remains on the role of NOX4 in mitochondria as much of the topological evidence
does not differentiate between NOX4-mediated ROS release and NADH-dependent superoxide
production from complex I [53]. This is further complicated by Dikalov et al. [54] and Takac et al. [55]
who propose that the primary ROS released from NOX4 is hydrogen peroxide not via the classical
superoxide mechanism. As a final point, while some researchers question the localisation of NOX4 in
mitochondria [46], a more likely supposition is that NOX4 are exclusively located in specialised cells
(kidney cortex, [56]; cardiac myocytes, [57]; vascular smooth muscle cells, [58]). Notwithstanding that
the lack of antibody-specificity for direct NOX4 quantification remains problematic, it is worth
considering that NOX4 may not fulfil a role in mitochondrial oxidative stress, and that other
mitochondrial sources (i.e., respiratory chain complexes) can significantly exceed the production
of ROS compared to NOX4 [59]. However, it is plausible to propose that extramitochondrial
NOX4 acts on the redox sensitive mitochondrial protein kinase Cε, mitochondrial ATP-sensitive
potassium channels, and/or thioredoxin 2 activity, subsequently increasing mitochondrial superoxide
formation from the ETC [53,60,61]. A final contributor to mitochondrial O2·−/H2O2 accumulation are
the monoamine oxidases (MAO) located in the outer mitochondrial membrane [62]. Menazza and
colleagues [63] demonstrated the importance of MAO on hydrogen peroxide generation in skeletal
muscle, thereby causing a loss of vitality and contractile impairments, partially related to myofibrillar
protein oxidation. Contentiously, data from substrate-dependent oxidation studies suggests that MAO
are potentially the most potent of all mitochondrial hydrogen peroxide producers; estimated to be
48 times more prolific than complex III (in the presence of antimycin: tyramine 45.2 µM/s versus
succinate 0.95 µM/s; [64,65]). Similar to the supposition presented by Menazza et al. [63], inhibition
of MAO attenuated mtDNA damage [65]. Caution is warranted regarding the contribution of MAO
to hydrogen peroxide accumulation in skeletal muscle tissue due to the nanomolar concentrations
of endogenous substrates [50]. Aside from the aforementioned sources, several other sites generate
superoxide, including pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transient quantal
superoxide flashes [66–68].
To date, the major limitation with examining the topology and capacities of mitochondrial ROS
is the lack of experimental and analytical approaches to empirically identify different production
sites under various physiological conditions (e.g., exercise). Recently, Goncalves and colleagues [69]
have pioneered the use of site-selective suppressors to inhibit O2−/H2O2 production from a single
site (IQ and IIIQo) without blocking electron flow and substrate utilization, whilst not disturbing the
membrane potential or energy transduction [70,71]. In a medium mimicking rest conditions, the major
contributors of O2·−/H2O2 production from C2C12 myoblasts were sites IIF, IQ and IF generating 24%,
23% and 20% respectively; this significantly decreased during exercise-mimicking conditions; however,
site IF generated 44% of total O2−/H2O2 [72]. Importantly, the concentration and type of substrate
oxidised, and the concentration and redox state of the electron-donating site, are the most salient factors
influencing the rate of O2·−/H2O2 release from the mitochondria [49,73]. Other contributing factors
include strength of the membrane potential, local oxygen tension, electron flux, protonmotive force,
ATPase activity, NADH availability, allosteric regulators, or posttranslational modifications [49,74,75].
Antioxidants 2020, 9, 1142 5 of 25
3. Mitochondria-Targeted Antioxidants
Mitochondria are inherently difficult to target, as not only are there anatomical, immunological,
and biochemical barriers to overcome, but the antioxidant compound must possess the physicochemical
properties to cross several membranes [76,77]. Current targeting strategies to overcome these barriers
(such as liposome enclosure, lipophilic cations, and targeted peptides) must exhibit several properties:
(i) ability to bind to the pharmacologically active form of the compound; (ii) an efficient transport
system that carries the compound to the site of its action; (iii) specific and selective targeting to the
mitochondrial compartment; and (iv) release of the compound inside the mitochondrion [22,78].
Lipophilic cations are commonly utilised largely due to their ability to use the mitochondrial
membrane potential (∆Ψm) to selectively target and accumulate in the mitochondrial matrix.
In accordance with the Nernst equation (∆Ψ(mV) = 61.5 × log 10 cincout ), this allows for a 10-fold
increase in diffusion and accumulation of lipophilic monovalent cations for every 61.5 mV of membrane
potential [79]. Additionally, the electrochemical gradient from the plasma membrane potential (−30
to −60 mV) to the inner mitochondrial membrane potential (−150 to −180 mV) selectively targets
large lipophilic cations to the mitochondria; this negative potential is specific to the mitochondria in
comparison to other subcellular organelles. By using lipophilic cations, Sheu et al. [80] estimates that
accumulation of specific compounds can increase 100- to 1000-fold in the mitochondria matrix.
Triphenylphosphonium (TTP+) is particularly effective, as it is relatively easy to introduce into a
compound by displacing a leaving group by reaction with triphenylphosphine [(Ph)3P+-R]; allowing for
a rapid accumulate of compound in the mitochondrial matrix [29]. The application of TPP+-conjugated
bioactive molecules have been developed to deliver antioxidants, redox probes, and pharmacological
agents to the mitochondria (Figure 2) [81–83]. These mitochondria-specific moieties are reported to
react with a variety of redox modulators including hydrogen peroxide, nitric oxide, peroxynitrite, lipid
peroxyl and alkoxyl radicals. With that being said, TPP+-conjugates are not without drawbacks: (i) they
may be limited to low molecular weight molecules and electrically neutral chemicals; (ii) affected by
mitochondrial sublocalization (i.e., the targeting of processes that occur on the outer leaflet of the inner
mitochondrial membrane, the outer mitochondrial membrane, or the intermembrane space is largely
limited or impossible); and (iii) high concentrations can result in depolarising of the ∆Ψm, thus altering
cell viability [22,84,85].
3.1. MitoQuinone, 10-(6V-Ubiquinolyl)Decyltriphenylphosphonium Bromide and
10-(6V-Ubiquinonyl)Decyltriphenylphosphonium Bromide
Coenzyme Q10 (CoQ10) is a benzoquine (2,3-dimethoxy-5 methyl-6-decaprenyl-benzoquinone)
and is synthesised endogenously from the acetyl-CoA-mediated mevalonate cycle [87].
The physiological oxidoreductase properties of CoQ10 allow it to act as an electron transporter
between NADH dehydrogenase and succinate dehydrogenase, and from succinate dehydrogenase
to the cytochrome bc complex [87]. Selectively targeting CoQ10 to the mitochondria is limited by
high lipophilicity, large molecular weight, and poor aqueous solubility; consequently, clinical trials
often administer high doses (≥200 mg/day) to support prophylactic outcomes [88,89]. To overcome
this, a TPP+ moiety of ubiquinol (mitoquinone [MitoQ]) comprised of a 10-carbon alkyl chain was
developed by Robin Smith and Michael Murphy [90,91]. MitoQ accumulates at the matrix-facing side
of the inner mitochondrial membrane where it is recycled by complex II into the active ubiquinol
form (MitoQH2). Due to sublocalisation, MitoQ is effective against mitochondrial lipid peroxidation
and peroxynitrite-induced damage by donating a hydrogen atom to oxygen-centred radicals, thereby
inhibiting oxidative damage to mitochondrial lipids, proteins and DNA; this reaction generates
ubisemiquinone that rapidly dismutates to ubiquinone and ubiquinol, with UQ recycled back to UQH2
by the mitochondrial respiratory chain (UQ + O2−↔ UQ− + Q2) [92]. An additional pathway worthy
of consideration is the potential of MitoQ to interact with hydroperoxyl radical species (E◦(HOO·,
H+/H2O2) = 1.44 V) by direct hydrogen transfer, thereby enabling superoxide to pass into biological
membranes and incite oxidative damage (UQH2 + R·/HOO· → UQH· + RH/H2O2; 2UQH· → UQ +
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UQH2) [93]. With that being said, it is unlikely that this pathway plays a significant role in biological
mediums given the slow rate reaction of UQH2 with R/HOO· (1−3 × 103 M−1 s−1) and the greater
affinity ofα-tocopherol for R/HOO· (2× 105 M−1 s−1) [94]. It is perhaps more plausible that UQH2 exerts
an antioxidant effect against R·/HOO·-mediated mitochondrial lipid peroxidation by regenerating
the α-tocopheroxyl radical (αToc + R·/HOO· → αToc· + H2O2; UQH2 + αToc· → αToc + UQH·) [93].
In summary, it seems MitoQ has the potential to exert a number of antioxidant effects in mitochondria
including: (i) oxygen-centred radical scavenging; (ii) α-tocopherol recycling; and (iii) direct reaction
with superoxide; yet, under certain conditions it may exert pro-oxidant effects. On the latter, and
for a comprehensive overview on the underlying biochemistry, readers are directed towards more
established reviews [86,95]; however, for the purpose of brevity, in damaged membranes or close to the
membrane surface, UQH2 can autoxidise, propagating the generation of the ubisemiquinone radical
and downstream formation of superoxide and hydrogen peroxide [96,97].
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3.2. SkQ1, Plastoquinonyl-Decyl-Triphenylphosphonium
While it is evident that MitoQ is effective against oxidative damage, there is potential for partially
reduced and/or protonated intermediate forms to act as pro-oxidants through interaction with oxygen
to form superoxide [92]. This presents a limitation for their therapeutic use in elevated oxidative stress
scenarios [98,99]. To address this, ubiquinone was substituted for plastoquinone, thereby allowing for a
32-fold increase in the anti- versus pro-oxidant concentrations to be preferentially differentiated (MitoQ,
~300 and ~500 nM; SkQ1, ~25 and ~800 nM, respectively, [100,101]). In addition to the dampened
pro-oxidant potential of SkQ1, SkQ1H2 (the reduced form) has a greater antioxidant capacity in
comparison to MitoQ [83]. Similar to MitoQ, SkQ1 is reduced by the respiratory chain to SkQ1H2 and
acts to prevent peroxidation of mitochondrial cardiolipin and superoxide formation [100,102]. Initially,
the administration of SkQ1 was directed towards artificial lipid membranes, isolated mitochondria
and animal models [101]; however, due the abundance of polyunsaturated fatty acids and exposure
to atmospheric oxygen, research involving SkQ1 as a therapeutic was directed towards Phase I
ophthalmic applications [103,104]. In tandem, the development of oral and injectable forms of SkQ1
and its analogue SkQR1, is a current active area of clinical research [101].
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3.3. Szeto-Schiller Peptide-Based Strategies
In addition to the presented lipophilic-conjugated antioxidants, a series of Szeto-Schiller (SS)
peptides (SS-19, SS-02, SS-31, SS-20) have been examined for their therapeutic potential as they
can readily cross cell membranes and enter mitochondria due to their alternating aromatic-cationic
amino acid motif [105]. Antagonistic to lipophilic-targeted molecules, SS-peptides do not rely on
mitochondrial membrane potential as demonstrated on depolarised mitochondria and in the presence
of an uncoupler (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) [106]. The mechanism of
peptide mitochondrial uptake is not entirely clear, however SS-peptides are known to accumulate
1000–5000-fold and localise at the inner mitochondrial membrane via electrostatic and hydrophobic
interactions [107,108].
The antioxidant properties of SS-peptides are attributed to their tyrosine or dimethyltyrosine
residue allowing them to scavenge ROS effectively. It appears that the addition of dimethyltyrosine
within SS-31 and SS-02 make them particularly effective at scavenging hydroxyl and peroxynitrite
free radicals, with the possibility of also interacting with peroxyl radicals [109]. The protective effects
of these peptides have been demonstrated in vitro in comorbidities associated with diabetes, such as
retinopathy [110]. Similar in vivo observations are evident in animal models of human pathologies
such as myocardial infarction [111], obesity [100] and ischemic brain injury [112]. From the literature,
it appears the SS-31 moiety presents the greatest efficacy for prophylaxis due to its ability to bind to and
protect against cardiolipin peroxidation by altering cytochrome c peroxidase activity [113]. To date,
SS-31 has been developed as a pharmacological agent (as Bendavia/Elamipretide) and has undergone
Phase I and II clinical trials (NCT02388464, NCT01572909, and NCT02367014 [114]).
3.4. Other Mitochondria-Targeted Compounds
The majority of research on targeted molecules has been on the aforementioned
antioxidants, however, a range of mitochondria-targeted compounds have been developed
using conjugated-technology with the purpose of mitigating the mitochondrial ROS cascade.
The development of MitoSOD (a macrocyclic SOD mimetic) by Kelso et al. [115] allows for the
selective reaction with mitochondrial superoxide above that provided by the endogenous MnSOD
enzyme alone. A second SOD mimetic worthy of highlighting is MitoTEMPOL which acts to detoxify
ferrous iron by oxidising ferric iron, converting the superoxide anion to water. A mitochondria targeted
derivative of Ebselen (a glutathione peroxidase mimetic [MitoPeroxidase]), attenuates lipid peroxidation
and prevents apoptotic cell death by clearing hydrogen peroxide [116]. Clearly, a wide variety of
avenues for redox-centred research are stemming from the development of mitochondria-targeted
compounds with the aim of (i) creating an array of targeted compounds for therapeutic human
interventional purposes, and (ii) to further understand the significance of complex mitochondria redox
signalling pathways.
4. Exercise and Mitochondrial Oxidative Stress
NADPH oxidase enzymes are primarily thought to drive exercise-induced O2− production, in part,
because several factors (notably ATP demand) should decrease mitochondrial O2− production [117].
Intriguingly, while net mitochondrial O2− production is decreased, the flavin mononucleotide of
complex I continues to produce O2− in a metabolic milieu mimicking exercise in isolated mitochondria
from hind limb skeletal muscle of Wistar rats [69]. As a result, the persistent nature of mitochondrial
O2·− production means a low rate of net production can cause damage over time. Furthermore,
it could be hypothesised that as exercise intensity increases, H2O2 production from the electron
transport chain decreases while simultaneously increasing the ability of the mitochondria to sequester
extramitochondrial H2O2; thereby increasing the likelihood of Fenton-mediated reactions, and
subsequent mtDNA damage. In addition to our limited understanding of the effects of exercise
on mitochondrial oxidative stress, the use of non-specific, pleiotropic antioxidants makes it difficult to
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draw any precise mechanistic or practical conclusions. To that end, the following sections (i) detail our
current knowledge and understanding of exercise-induced perturbations to mitochondrial oxidative
stress, and (ii) offers potential implications for the use of targeted antioxidant supplementation.
Fogarty and colleagues [118] were the first to demonstrate the impact of exercise on mtDNA by
showing that isolated and maximal contractions increased mitochondrial 8-hydroxy-2-deoxyguanosine
concentration in vastus lateralis muscle tissue. More recently, we have demonstrated an increase
in global mtDNA damage in peripheral blood mononuclear cells and skeletal muscle (as quantified
using LA-qPCR) following high-intensity intermittent exercise [119]. It is highly likely the observed
mtDNA damage originated from O2−/H2O2-derived mechanisms, stemming from their ability to
react with accessible transition metals to produce damaging hydroxyl free radical species via Fenton
chemistry (H2O2 + Fe2+→ Fe3+ + −OH + ·OH [k ~ 76 M−1 s−1]; H2O2 + Cu+→ Cu2+ + −OH + ·OH
[k ~ 4.7 × 103 M−1 s−1]) [120]. As a result, the hydroxyl free radical appreciably reacts with DNA
bases at diffusion-controlled rates (k ~ 5–8 × 109 M−1 s−1 for guanine [121]); potentially generating
other end products, which can further propagate oxidative damage [122]. Interestingly, a recent
supposition proposes that the carbonate radical anion as opposed to the hydroxyl free radical is the
predominate radical formed from the Fenton reaction (FeII(CO3)(OOH)(H2O)2→ FeIII(OH)3(H2O) +
CO3·−) [123,124]. Given the reduction potentials of both the hydroxyl and carbonate radicals (2.4 and
1.6 V, respectively), it is not surprising that 2′-deoxyguanosine is a common outcome for these potent
one-electron oxidants. With that being said, the biological relevance and implications of the carbonate
radical in Fenton-mediated chemistry and subsequent oxidative damage is yet to be ascertained.
Historically, it was understood that exercise-induced superoxide predominately originated from
the respiratory chain [32]; however, recent estimations suggest greater concentrations of mitochondrial
superoxide are produced during State 4 respiration (i.e., basal) in comparison to State 3 (i.e., exercise).
Additionally, although the intricacies of NADPH oxidases are complicated, the mitochondrial NOX4 is
constitutively active and likely contributes to basal O2·−/H2O2 production in skeletal muscle tissue.
Furthermore, it appears evident that contraction-induced superoxide production is largely derived
from non-mitochondrial sources; specifically NOX2 due to agonist activation (e.g., angiotensin II,
cytokines, and mechanical stress) [125–127]. Notwithstanding the potential for delayed mitochondrial
redox dynamics, collectively, the apparent decrease in exercise-mediated mitochondrial O2−/H2O2
production as suggested by Goncalves et al. [69], in tandem with the observed increase in mtDNA
damage [118,119], presents a major paradoxical juxtaposition of our understanding of mitochondrial
redox dynamics in the context of exercise. While much of the topological research of mitochondrial
O2·−/H2O2 generation has focused on the specific complexes of the respiratory chain [69,72], others
have shown correlations between mitochondrial H2O2 generation and P66Shc-FOXO3a expression in
an intensity-dependent manner in the skeletal muscle of mice [128,129]. With that being said, the
narrative that P66Shc is responsible for the accumulation of mitochondrial H2O2 and consequential
mitochondrial oxidative damage as a function of exercise, albeit biologically plausible, is unfounded;
especially in the in/ex vivo human model.
An additional proposition worth discussing is for the exercise-induced H2O2 to be a nexus
point of nuclear and mitochondrial redox signalling [130]. The mitochondria play a dichotomous
role in the production and degradation of H2O2 [131,132]; however, they also have the potential
to quench extramitochondrial or cytosolic H2O2 when the rate of O2·− release from the respiratory
chain is low (i.e., during exercise [69,72]) and via the glutathione and thioredoxin systems [133–135].
Murphy [136] outlines that mitochondrial H2O2 has a large capacity for diffusion, and is hypothesised
to play distinct roles in downstream physiological signalling responses, including post-translational
modifications [131,137]. It is clear that low-to-moderate intensity/duration exercise exerts ROS-mediated
triggers for adaptation signalling with minimal DNA damage [138]; however, as exercise intensity
increases, so too does damage to DNA [139]. It could be hypothesised that as exercise intensity
increases, mitochondria act as an ‘antioxidant’ per se by sequestering cytosolic H2O2 and dissipating
it through the catalase, glutathione, and thioredoxin antioxidant systems [140]. This ability of the
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mitochondria to quench cytosolic H2O2 has been demonstrated by others [133,141]; however, it appears
to be largely dependent on (i) the rate of mitochondrial hydrogen peroxide production, and (ii) the rate
of mitochondrial H2O2 degradation [135].
5. Exercise-Induced Mitochondrial Oxidative Stress and the Role of Targeted Compounds
Research examining exercise-induced oxidative stress and antioxidants largely focuses on
two primary outcomes: (i) induction/attenuation of macromolecular damage, and (ii) the redox
signalling of exercise adaptation [10,142]. Over the last two decades there has been a paradigm
shift in our understanding of exercise-induced oxidative stress and antioxidants; firstly, the ability of
reactive species and antioxidants to improve exercise performance, and secondly, the implications of
antioxidant supplementation on exercise adaptation [6,143]. Given the role of oxidative stress and
antioxidant supplementation on exercise redox biology, and the emerging importance of redox-mediated
retro/antero-grade signalling (i.e., mitochondrial-nuclear communication), our understanding of the
role of exercise-induced perturbations to mitohormesis and mitochondrial-targeted compounds is
limited. In this section, we attempt to propose the role of mitochondrial-targeted compounds on the
potential implications for exercise and oxidative damage to mitochondrial macromolecules.
5.1. Mitochondrial DNA Damage
Mitochondria contain a polyploid, 16,569 base pair circular genome which can be categorised
as homo or heteroplasmy depending on the sequencing of multiple copies within the cell [144].
Maintaining the integrity of the mitochondrial genome is important to prevent irreversible loss or
modification of its coded information, which is particularly detrimental in postmitotic tissue [145].
Free radical oxidants are known to produce an array of DNA oxidative modification, which may
be potentiated by the mitochondrial matrix microenvironment, and until very recently [146,147],
methodological and analytical techniques have lacked the specificity and sensitivity to detect the
board spectrum of mtDNA lesions [148]. Mitochondrial DNA is particularly susceptible to oxidative
attack, resulting from the close proximity of the genome (and abundance of cardiolipin and secondary
peroxidative products) to multiple sources of mitochondrial superoxide, lack of protective histone
proteins, and limited capacity for repair [39,149–151]. Consequently, genetic information is more
tightly packed, resulting in higher relative levels of oxidative damage in comparison to the nuclear
genome; thus amplifying the potential downstream detrimental and mutational effects [145]. For one,
correlations between mitochondrial ROS and mtDNA strand breaks suggest that greater DNA damage
has the potential to incite a greater formation of mtROS as impaired mtDNA translation leads to
mitochondrial uncoupling with secondary increases in mtROS formation [152]. To elaborate, one of the
most common oxidative modifications, 8-oxo-deoxyguanosine, is a potential mutagenic lesion, and its
accumulation is directly correlated with the development of pathological processes [153,154]. Finally,
selective mtDNA variants are an underlying factor in mitochondrial diseases and other pathologies;
thus clarity on the downstream beneficial/detrimental consequences of oxidative mtDNA damage is
warranted [155].
Beyond the observable increase in mtDNA damage following exercise, our current understanding
of the effects of this damage, on mitochondrial redox dynamics (and indeed signalling) is unknown.
The observations by Fogarty and colleagues [118] provide tentative evidence for a Fenton-mediated
mechanism of hydroxyl attack on DNA; however, it is worth noting that these analyses were
performed on isolated mitochondria from muscle tissue which have the potential to incite artefactual
oxidation. To help address this, we recently used long amplicon-qPCR to ascertain the effect of
high-intensity intermittent exercise on mitochondrial DNA. Following 4 × 4-minute bouts of exercise,
we observed an increase in mtDNA damage (lymphocytes and muscle tissue), and detectable changes
in lipid peroxidation and the ascorbyl free radical; some of which was mitigated by chronic MitoQ
supplementation (20 mg/day for 3 weeks [119]). In both instances, the exercise-induced mtDNA damage
is likely initiated by: (i) inhibiting repair; (ii) increasing H2O2 production; and/or (iii) increasing
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the labile redox-active transition metal pool via hydroxyl (and potentially peroxynitrite-derived)
radicals [120,122].
The role of exercise-induced mtDNA damage is enigmatic, and although generally considered
harmful, the current lack of understanding associated with mtDNA allows scope for oxidative damage
adducts to initiate or act as beneficial signals. One proposition is for oxidative modifications to DNA
(e.g., 8-oxo-deoxyguanosine) to trigger the upregulation of repair genes and other genes that need to
respond to the perturbations in cellular and/or mitochondrial redox state [124]. Additionally, DNA
repair pathways help prevent heteroplasmy and maintain genome integrity; however, conjecture
still surrounds whether these repair enzymes pre-exist in mitochondria at the time of damage or
translocate into the mitochondria in response to damage signals [156]. These antero/retrograde
signalling processes between the mitochondria and nucleus respond to a loss of mtDNA, damage
accumulation, and oxidative stress trigger signals, ultimately dictating downstream organelle and/or
cellular adaptations [157–159]. Firstly, mtDNA damage causes a rise in calcium concentration, leading
to an activation of protein kinase C, c-Jun N-terminal kinase/p38 and Ca2+/calmodulin-dependent
protein kinases that are not only linked to post-translational modifications to DNA repair proteins,
but also are contributing factors in the signal transduction pathway of mitochondrial biogenesis [160].
Secondly, NAD+ is a critical substrate for the PARP and SIRT families which deacetylate and activate
a complex network of proteins associated with the DNA damage-repair response and cellular
adaptation (i.e., PGC1α, Ku70, NF-κβ, and NIF1α [161]). Finally, p53 and ataxia telangiectasia
mutated are redox-sensitive and can function to phosphorylate and activate AMP-activated protein
kinase, subsequently regulating the activity of the previously mentioned anterograde signalling
triggers (SIRT1, PGC-1α, and HIF-1α). To conclude, while exercise increases the accumulation of RONS
which trigger the activation of downstream transcription factors it also appears that oxidative- and
mitochondrial-stress (including mtDNA damage) modulate redox-sensitive triggers (Ca2+, ATP:AMP,
NAD+:NADH) which signal for adaptations associated with mitochondrial biogenesis, metabolism, and
maintenance of genome integrity [156,160,161]. Interestingly, it has been hypothesised that oxidative
stress activates mitochondrial DNA methyltransferases, which promote epigenetic modifications
responsible for mitochondrial transcription and promote the accumulation of mitochondrial and
nuclear 8-hydroxy-2′-deoxyguanosine [162,163].
5.2. Mitochondrial Lipid Peroxidation
The mitochondria contain a high prevalence of lipids such as anionic cardiolipin,
phosphatidylethanolamine, and phosphatidylcholine, which are vulnerable to oxidative attack at
varied rates initiated by RONS (e.g., hydroxyl radicals, superoxide, peroxyl radical, nitric oxide,
peroxynitrite or nitrogen dioxide) [164]. These accumulated phospholipids, in combination with the
high rate of oxygen utilisation and peroxidative catalysts (i.e., heme and non-heme iron), potentiate
oxidative damage to mitochondrial lipids which can contribute to mitochondrial dysfunction [165], the
pathogenesis of inflammation [166], and numerous age-related diseases [167,168]. In addition to this
direct oxidative insult, lipid peroxidation products may contribute to DNA damage, thus propagating
the oxidative damage cascade; this may partially explain the elevated mitochondrial mutations observed
in diseases and inactive respiratory complexes [169,170]. Although there are a variety of peroxidative
targets, it appears that cardiolipin is a central component of mitochondrial oxidative stress. For one, it
is the most sensitive constituent of the inner mitochondrial membrane [100]. Secondly, cardiolipin acts
as an anchor for cytochrome c and mtDNA (specifically during replication), of which peroxidative
attack results in cytochrome c release, accumulation of apoptosis factors, and propagation of the
peroxidation cascade [171–173]. Finally, loss of cardiolipin results in inhibition of respiratory chain
complexes, H+-ATP-synthase, ATP/ATP-antiporter subsequently leading to an increase in permeability
of the inner mitochondrial membrane and, as a consequence, resulting in the collapse of ∆ψ, swelling
of matrix, disruption of the outer mitochondrial membrane and release of cytochrome c into the
extramitochondrial space [174].
Antioxidants 2020, 9, 1142 11 of 25
It is worth highlighting the significance of exercise-mediated lipid peroxidation in relation to DNA
damage, as these biological scenarios are intertwined [139]. Briefly, the formation of a lipid radical can
give rise to various lipid peroxidation products including lipid hydroperoxides, alkoxyl radicals, and
aldehydes [175]. Aldehydes in particular can react with DNA, and it is known that malondialdehyde can
lead to mutagenic insertions, deletions, and base pair substitutions, and can react with nitrogen to form
the malondialdehyde-2′-deoxyguanosine adduct. The compound 4-hydroxy-2-nonenal interacts with
DNA including Michael addition of the N2-amino group of deoxyguanosine resulting in the formation
of the γ-hydroxy-1,N2-propano-2′-deoxyguanosine adduct [175–177]. We have previously shown that
exercise-induced DNA damage is associated with lipid-derived alkoxyl free radical production, and this
occurred in the presence of raised lipid hydroperoxides [139]. Thus, given that mitochondrially-targeted
antioxidants are effective at scavenging the by-products of lipid peroxidation [80,170,178], attenuating
exercise-induced lipid peroxidation may decrease the harmful effects of downstream DNA damage.
Initially, much of the research focused on MitoQ due to its ability to (i) accumulate in mitochondria
in a ∆ψ-dependent manner; (ii) act as an effective antioxidant against hydroxyl-mediated mitochondrial
lipid peroxidation; (iii) facilitate cell survival at much lower concentrations than CoQ or α-tocopherol;
and (iv) prolong longevity at high O2 tension [82,100,179]. However, the ability of MitoQ to act as an
antioxidant changes to a prooxidant when MitoQ concentration is increased (e.g., 0.5–1 µM versus
2 µM on hydrogen peroxide production) [100,102,104]. As a result, derivatives of targeted quinone
compounds were prioritised due to the larger antioxidant versus prooxidant window. In a series of
seminal experiments, Skulachev and colleagues [83] characterised cationic antioxidants within the
propagation phase of lipid peroxidation (LO2• + QH2→ LOOH + QH• vs. LO2• + LH→ LOOH + L•).
They suggested the antioxidant effects of plastoquinone-derived compounds against mitochondrial
lipid peroxidation are two-fold: (i) direct quenching of radical intermediates of cardiolipin peroxidation
([1] LO2· + SkQH2 → LOOH + SkQ−·, [2] O2-z· + SkQ → O2 + SkQ−·) and (ii) potentiating
mild uncoupling by mediating the transport of fatty acid anions ([3] (RCOO-)inSkQ(RCCO-)out, [4]
(LOOH)inSkQ(LOOH)out); however, this latter mechanism may be contentious in MitoQ or SkQ1 in
comparison to dodecyltriphenylphosphonium (C12TPP).
5.3. Implications for Exercise
The initial proposition that ROS are inherently detrimental to health suggests that synthetic
antioxidants may be used to reduce oxidative damage, thus offering a potential therapy to pathological
outcomes. Later, the shift in paradigm uncovered the paradoxical beneficial roles of ROS in
pathophysiology. This curvilinear relationship between ROS and oxidative stress also appears to be true
for the use of antioxidant supplementation. Currently, it is apparent that antioxidant supplementation
seems to play dichotomous roles regarding exercise: (i) the improvement of cellular redox state
and decreased modifications to DNA, lipids, and proteins via the neutralisation of exercise-induced
ROS generation leading to possible impairments in the adaptive changes associated with chronic
exercise [7,180–182], and (ii) based on the original hypothesis by Reid [183], exogenous antioxidant
supplementation can sustain muscle contraction and exercise performance [138,184,185]. Nevertheless,
this juxtaposition of systemic antioxidants (whether sole or in combination) and the implications for
exercise is beyond the scope of this review, and readers are directed towards the more nuanced works
of Mason et al. [186], Merry & Ristow [187], and Reid [188].
The role of mitochondria-targeted antioxidants on both the acute and chronic responses of exercise
redox physiology is an active area of research. Although N-acetylcysteine has been shown to be
particularly effective in improving exercise fatigue tolerance [189,190]—likely through the regulation of
ROS—mitochondrial-targeted antioxidants don’t appear to have the same efficacy. Interestingly, Cheng
and colleagues [81] demonstrated that although effective at sequestering mitochondrial superoxide,
SS-31 had no impact on fatigue in mouse muscle, suggesting that ROS-induced fatigue is mediated by the
cytosolic ROS challenge, possibly resulting from modifications to cellular Ca2+ handling. Additionally,
Siegel and colleagues [191] who reported a restoration in age-related decline in mitochondrial coupling
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efficiency, phosphorylation capacity, and PCr/ATP ratio, translating to an enhanced exercise fatigue
resistance and exercise capacity. Although this was demonstrated in an animal model, it supports the
notion that targeted antioxidants may have therapeutic benefits in mitochondrial dysfunction scenarios.
Indeed, our recent work [119] failed to detect any changes in basal mtDNA damage following chronic
MitoQ supplementation; however, it did reduce exercise-induced mtDNA damage. We propose that
the use of MitoQ may be limited in healthy individuals with low basal oxidative damage [11,192];
however, targeted supplementation may show efficacy in conditions characterised by chronic oxidative
stress and/or mitochondrial dysfunction [193–195].
Although the human evidence on MitoQ is limited, the clinical evidence appears to confirm
this hypothesis with promising results of MitoQ therapy in Parkinson’s disease [196], Hepatitis
C-induced liver damage [197], and vascular dysfunction [28]. More recently, other researchers have
demonstrated a dose-dependent increase in exercise performance in patients with mitochondrial
myopathy following SS-31 administration, likely through modulating ATP synthesis [198]. Although
there is a putative mechanism and safety with targeted antioxidants (specifically MitoQ and SS-31),
and the emerging evidence suggests a therapeutic potential for clinical applications, it doesn’t
appear to translate to any measure of exercise performance in healthy individuals [199]. It seems the
premise for antioxidant supplementation as an ergogenic aid for improving exercise performance and
fatigue resistance is largely driven through the redox state of the cytosolic environment and systemic
antioxidant status as opposed to the mitochondrial compartment. With that being said, it is evident
that mitochondria-targeted compounds act on various parameters of muscle, such as mitochondrial
function and capacity, contractile function, and insulin sensitivity [200]. A call for future research is
warranted to elucidate whether the: (i) promising results achieved in the animal model are aligned
to humans, (ii) acute reduction in mitochondrial ROS translates to an ergogenic effect through the
consumption of single or combinations of mitochondria-targeted antioxidants, and (iii) beneficial
effects associated with targeted antioxidants are exclusively applicable to clinical populations, or in
individuals with elevated basal mitochondrial oxidative stress.
The acute exercise responses to antioxidants are only one face of the coin: Merry & Ristow [187]
and Reid [188] have published comprehensive reviews discussing whether synthetic antioxidant
supplementation hampers the chronic responses of exercise in skeletal muscle through the blunting of
redox-signalling pathways. As a general consensus, it seems there is a lack of conclusive evidence
for most antioxidant compounds regarding exercise-related redox signalling and the subsequent
adaptations in skeletal muscle and vascular function [186]; indeed, this is of course more applicable
for targeted-antioxidant applications. Shill and colleagues [199] are the only group to investigate
the effects of chronic mitochondria-targeted antioxidant supplementation (MitoQ; 10 mg/day for 3
weeks) on exercise training-induced adaptations and performance outcomes in healthy young men,
with no observable effects on V.O2max, oxidative capacity, or circulating angiogenic cells reported.
This supports the hypothesis that antioxidant supplementation may only be beneficial in populations
where chronic oxidative stress and perturbed redox homeostasis is likely to be present. Additionally,
Min et al. [201], (albeit within the animal model) demonstrated that treatment with SS-31 protected
skeletal muscle against the production of mitochondrial ROS, mitochondrial uncoupling, oxidative
damage, and inactivity-induced atrophy. It was concluded that mitochondrial ROS and subsequent
oxidative damage triggered upstream alterations in cytosolic free Ca2+, activating calpain and capase-3,
in turn causing skeletal muscle atrophy. This provides a tentative hypothesis for the beneficial blunting
of adaptation signalling through mitochondrial ROS.
Several lines of research suggest that mitochondrial ROS are implicated in retrograde signalling
to the nuclear genome to stimulate a biogenic response, possibly to replace oxidatively damaged
mitochondrial proteins or DNA [202,203]. Indeed, mitochondrially-produced ROS contribute to
phosphatase inactivation and insulin receptor autophosphorylation [204,205], in addition to the
phosphorylation of phosphatidylinositol 3 kinase and downstream activation of AKT signalling;
a process core to cell survival and mitochondrial biogenesis [206,207]. It is evident that acute stimulation
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with exogenous oxidants activates mitochondrial biogenesis [208,209], either through PGC-1α- or
PI3K/AKT-mediated pathways [210]. The redox-activated PGC-1α is also associated with the expression
of antioxidant genes such as Prx3, Prx5, Trx2, TrxR2, catalase, SOD2, and GPx-1 [211,212]. Additionally,
mtDNA damage signals for mtDNA degradation as an important damage response mechanism to
maintain genomic integrity [213–215]. Supporting evidence suggests that the mtDNA degradation
pathway is more important in reducing the abundance of oxidative DNA lesions and mutagenesis
than the inferred lack of mtDNA repair pathways reported in earlier studies [216,217]. Collectively,
there is ample evidence that mitochondrial ROS are implicated in numerous signalling pathways
such as apoptosis, autophagy/mitophagy, necrosis, and pyroptosis through activation of multiple core
signalling factors including AMP-activated protein kinase, mitogen-activated protein kinase kinase
kinase/mitogen-activated protein kinase 8, Ca2+ kinase II, cyclic adenosine monophosphate response
element binding protein, and nuclear factor-κβ pathways [218–220]. As recently highlighted by
Burtscher and colleagues [221], there is an urgency to examine whether a reduction in mtDNA damage
following targeted supplementation is independent of beneficial molecular and physiological exercise
adaptations under conditions of reduced redox signalling, and if there are consequences, for example,
on muscle fatigue and muscle damage. Examining modifications to mitochondrial redox dynamics are
complex (as outlined in Figure 3) due to the interplay between mitochondrial ROS generation, oxidised
mtDNA and lipids, and downstream signaling; however, the proposed use of mitochondria-targeted
compounds to alter this network presents a poignant call for carefully planned research.
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mitochondrial O2−/H2O2 generation and downstream consequences. Potential sources of mitochondrial
O2−/H2O2 (as indicated by the red star) include complex I, complex II, complex III, mGPDH, ETF/ETFQO,
DHODH, MAO, NOX4 and P66Sch allow for the release of O2·−/H2O2 into the inner mitochondrial
space, or the mitochondrial matrix. Mitochondrial superoxide is dismutated to hydrogen peroxide by
Mn-SOD. Hydrogen peroxide can act as an extramitochondrial signal transducer, or in the presence
of liable transition metals can undergo Fenton (FeIIaq+H2O2) chemistry causing oxidative damage
to mtDNA and cardiolipin. Damage to mtDNA can (i) activate signal transduction associated with
mtDNA repair, and/or (ii) induce mitochondrial dysfunction, subsequently leading to the propagation
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of mitochondrial O2·−/H2O2 and further oxidative insult. Depending on the sublocalisation, cardiolipin
oxidation can result in, (i) the release of cytochrome c to the cytosol, signalling for apoptosis/necrosis,
(ii) the generation of lipid peroxidation by-products capable of attacking adjacent cardiolipin molecules
and damaging mtDNA, and (iii) respiratory chain complex and mitochondrial dysfunction, thus further
propagating the mitochondrial oxidative cascade. It is difficult to ascertain the role exercise plays
in the schematic, not to mention the addition of mitochondrial-targeted antioxidants. Targeted
supplementation may attenuate the detrimental effects associated with mitochondrial O2·−/H2O2
generation (as outlined by the red arrows) while acting independent to the beneficial effects of
exercise adaptation and genome maintenance (as outlined by the green arrows). Abbreviations: OH·,
hydroxyl free radical; CL, cardiolipin; CL-OO·, cardiolipin-peroxyl radical; Cyt C, Cytochrome C;
DHODH, dihydroorotate dehydrogenase; ETFQOR, electron transferring flavoprotein:ubiquinone
oxidoreductase; Fe2+/Cu2+, iron/copper; FET, forward electron transfer; H2O2, hydrogen peroxide; IMM,
inner mitochondrial membrane; IMS, intermembrane space; OMM, outer mitochondrial membrane;
MAO; monoamine oxidase; mGPDH, mitochondrial glycerol-3-phosphate dehydrogenase; MnSOD,
manganese superoxide dismutase; NOX4, NADPH oxidase isoform 4; O2·−, superoxide; OMM, outer
mitochondrial membrane; Q, Ubiquinone; QH2, Ubiquinol; RET, reverse electron transfer; nDNA,
nuclear DNA.
6. Conclusions and Future Perspectives
Mitochondrial DNA damage in the context of exercise is an exciting area of emerging research with
many avenues to be explored. To the authors knowledge, only two studies have examined the effects
of exercise on mtDNA damage, highlighting that research examining the role of mitochondria-targeted
antioxidants on exercise-mediated changes to mitochondrial oxidative dis/eustress is very much in
its infancy. As such, there is a need for future research to ascertain the effects of exercise on mtDNA
modification and redox dynamics. The authors propose that further work should consider (i) whether
mitochondrial oxidative damage may be a molecular trigger for exercise-related cell adaptations,
(ii) the role of targeted antioxidants in the regulation of exercise performance, (iii) whether the
regulation of mitochondrial redox status through targeted antioxidants is exclusively beneficial to
clinical populations with elevated basal mitochondrial oxidative stress. To this end, we hope that
this narrative stimulates further research aligned to exercise-induced mtDNA damage and targeted
antioxidants across healthy and disease models.
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